Left Atrial Thrombosis Despite Dabigatran Therapy

Journal of Atrial Fibrillation
Anil PanditJohn J Lynch

Abstract

Dabigatran is a novel anticoagulation which has been approved as an alternative to warfarin therapy for non-valvular atrial fibrillation. Use of Dabigatran for approved indications as well as off label use has dramatically increased after Federal Drug Administration (FDA) approval. Our patient had left atrial thrombosis even after being on Dabigatran for more than one month which raises question about safety and efficacy of use of dabigatran around cardioversion and ablation.

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Related Papers

Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology
S Scardi
Circulation Journal : Official Journal of the Japanese Circulation Society
Naohiko Takahashi
Journal of the American College of Cardiology
Lawrence Gage
© 2022 Meta ULC. All rights reserved